Mesothelin Expression Is a Prognostic Factor in Cholangiocellular Carcinoma

Abstract Although mesothelin is highly expressed in epithelial mesotheliomas, and also in adenocarcinomas of the ovary and pancreas, the clinical significance of mesothelin in cholangiocellular carcinoma (CC) has not been reported, and its biologic features are largely unknown. In the present study, mesothelin expression was evaluated in 25 patients with CC using a well-characterized mesothelin monoclonal antibody (5B2). A total of 8 of the 25 patients with CC (32%) showed mesothelin immunoreactivity. The 25 patients were divided into 2 groups according to the percentage of tumor cells that were positive for mesothelin expression: negative (n = 17) or focally positive (mesothelin expression evident in less than 50%, n = 4; total, n = 21 for both groups), and positive (mesothelin expression evident in 50% or more, n = 4). The survival periods in both groups were statistically analyzed. The negative/focally positive group showed significantly longer postoperative survival than the positive group (P = 0.006). Also, mesothelin positivity was identified as an independent predictor of short postoperative survival. The present results suggest that mesothelin expression is a prognostic indicator in patients with CC.

Download Full-text

Presence and significance of NK cells in glioblastomas

Journal of Neurosurgery ◽

10.3171/jns.1989.70.5.0728 ◽

1989 ◽

Vol 70 (5) ◽

pp. 728-731 ◽

Cited By ~ 25

Author(s):

Jesús Vaquero ◽

Santiago Coca ◽

Santiago Oya ◽

Roberto Martínez ◽

Josefa Ramiro ◽

...

Keyword(s):

Monoclonal Antibody ◽

Nk Cells ◽

Survival Time ◽

Tumor Cells ◽

Lymphocytic Infiltration ◽

Surface Marker ◽

Content Type ◽

Hematoxylin And Eosin ◽

Hematoxylin And Eosin Staining ◽

Fine Print

✓ A monoclonal antibody against the surface marker IOT-10 of natural killer (NK) cells was used to investigate the presence of these cells in a series of 25 glioblastomas. In 40% of the tumors, IOT-10-positive NK cells were found in small numbers scattered among the tumor cells. The presence of IOT-10-positive NK cells was not related to the degree of lymphocytic infiltration in the tumor as demonstrated by hematoxylin and eosin staining, nor did it appear to influence the survival time of the patients studied.

Download Full-text

Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients

Cells ◽

10.3390/cells10071796 ◽

2021 ◽

Vol 10 (7) ◽

pp. 1796

Author(s):

Markus Eckstein ◽

Verena Lieb ◽

Rudolf Jung ◽

Danijel Sikic ◽

Katrin Weigelt ◽

...

Keyword(s):

Bladder Cancer ◽

Prognostic Factor ◽

Tumor Cells ◽

Immune Cells ◽

Potential Candidate ◽

Poor Prognostic Factor ◽

Risk Of Death ◽

Increased Risk ◽

Muscle Invasive ◽

Disease Specific

Urothelial bladder cancer (BCa) is the ninth most commonly diagnosed cancer worldwide and accounts for approximately 3% of global cancer diagnoses. We are interested in prognostic markers that may characterize tumor cells (TCs) and immune cells (ICs) and their relationship in BCa. A potential candidate marker that meets these criteria is progranulin (GP88), which is expressed separately in TCs and ICs. We analyzed GP88 expression by immunohistochemistry (IHC) in 196 muscle-invasive BCa samples using a tissue microarray. The immunoreactive score for GP88 staining in TCs and the percentage of GP88-positive ICs was determined. An easy cutoff for the staining status of TCs (positive vs. negative) and ICs (0% vs. >0%) and, more generally, negative vs. positive GP88 staining could be applied. We detected 93 patients (47.4%) and 92 patients (46.9%) with GP88-positive TCs or ICs, respectively. The IHC results were correlated with clinicopathological and survival data. Positive GP88 staining in TCs appeared to be an independent poor prognostic factor for disease-specific survival (DSS) (RR (relative risk) = 1.74; p = 0.009) and recurrence-free survival (RFS) (RR = 1.92; p = 0.002). In contrast, negative GP88 staining in ICs was an independent negative predictor for overall survival (OS) (RR = 2.18; p < 0.001), DSS (RR = 2.84; p < 0.001) and RFS (RR = 2.91; p < 0.001) in multivariate Cox’s regression analysis. When combining GP88 staining in TCs and ICs, a specific combination of GP88-positive TCs and GP88-negative ICs was associated with a 2.54-fold increased risk of death, a 4.21-fold increased risk of disease-specific death and a 4.81-fold increased risk of recurrence compared to GP88-negative TCs and GP88-positive ICs. In summary, GP88 positivity in TCs is a negative prognostic factor for DSS and RFS. In addition, GP88 positivity can mark ICs that are associated with a good prognosis (OS, DSS and RFS). The combination of GP88 staining in TCs and ICs appears to be a significant independent prognostic biomarker in muscle-invasive BCa.

Download Full-text

Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma

International Journal of Cancer ◽

10.1002/ijc.20347 ◽

2004 ◽

Vol 111 (5) ◽

pp. 741-745 ◽

Cited By ~ 45

Author(s):

Simone Mocellin ◽

Paolo Del Fiore ◽

Laura Guarnieri ◽

Romano Scalerta ◽

Mirto Foletto ◽

...

Keyword(s):

High Risk ◽

Prognostic Factor ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Cutaneous Melanoma ◽

Molecular Detection ◽

Independent Prognostic Factor

Download Full-text

Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas

Blood ◽

10.1182/blood.v69.2.584.584 ◽

1987 ◽

Vol 69 (2) ◽

pp. 584-591 ◽

Cited By ~ 246

Author(s):

OW Press ◽

F Appelbaum ◽

JA Ledbetter ◽

PJ Martin ◽

J Zarling ◽

...

Keyword(s):

Monoclonal Antibody ◽

Lymph Node ◽

B Cell ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

B Cell Lymphomas ◽

Antigenic Modulation ◽

Minor Response ◽

High Doses ◽

Anti Cd20

Abstract Four patients with refractory malignant B cell lymphomas were treated with continuous intravenous (IV) infusions of murine monoclonal antibody (MoAb) 1F5 (anti-CD20) over five to ten days. Dose-dependent levels of free serum 1F5 were detected in all patients. Two patients had circulating tumor cells and in both cases 90% of malignant cells were eliminated from the blood stream within four hours of initiation of serotherapy. Antigenic modulation did not occur, and sustained reduction of circulating tumor cells was observed throughout the duration of the infusions. Serial bone marrow aspirations and lymph node biopsies were examined by immunoperoxidase and immunofluorescence techniques to ascertain MoAb penetration into extravascular sites. High doses (100 to 800 mg/m2/d and high serum 1F5 levels (13 to 190 micrograms/mL) were required to coat tumor cells in these compartments in contrast to the low doses that were adequate for depletion of circulating cells. Clinical response appeared to correlate with dose of MoAb administered with progressive disease (52 mg), stable disease (104 mg), minor response (1,032 mg), and partial response (2,380 mg) observed in consecutive patients. The patient treated with the highest 1F5 dose achieved a 90% reduction in evaluable lymph node disease, but the duration of this remission was brief (six weeks). This study demonstrates that high doses of 1F5 can be administered to patients with negligible toxicity by continuous infusion and that clinical responses can be obtained in patients given greater than 1 g of unmodified antibody over a ten-day period.

Download Full-text

Alteration of plasma membrane of drug-resistant tumor cells: 230-Kilodalton protein identified by monoclonal antibody

Biochemical and Biophysical Research Communications ◽

10.1016/0006-291x(83)90655-1 ◽

1983 ◽

Vol 114 (3) ◽

pp. 969-975 ◽

Cited By ~ 9

Author(s):

Yoshikazu Sugimoto ◽

Hideo Suzuki ◽

Nobuo Tanaka

Keyword(s):

Monoclonal Antibody ◽

Plasma Membrane ◽

Tumor Cells ◽

Drug Resistant

Download Full-text

Monoclonal antibody internalization by tumor cells: an experimental model for potential radioimmunotherapy applications

International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology ◽

10.1016/0883-2897(89)90186-4 ◽

1989 ◽

Vol 16 (2) ◽

pp. 147-150

Author(s):

G Mariani ◽

A.D.V.D Abbeele ◽

C.N Venkateshan ◽

A Kaldany ◽

S Ito ◽

...

Keyword(s):

Monoclonal Antibody ◽

Tumor Cells ◽

Experimental Model

Download Full-text

Detection of Isolated Tumor Cells in Bone Marrow Is an Independent Prognostic Factor in Breast Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2003.02.009 ◽

2003 ◽

Vol 21 (18) ◽

pp. 3469-3478 ◽

Cited By ~ 176

Author(s):

G. Wiedswang ◽

E. Borgen ◽

R. Kåresen ◽

G. Kvalheim ◽

J.M. Nesland ◽

...

Keyword(s):

Breast Cancer ◽

Bone Marrow ◽

Prognostic Factor ◽

Tumor Cells ◽

Vascular Invasion ◽

Independent Prognostic Factor ◽

Histologic Grade ◽

Separate Analysis ◽

Node Negative ◽

Node Positive

Purpose: This study was performed to disclose the clinical impact of isolated tumor cell (ITC) detection in bone marrow (BM) in breast cancer. Patients and Methods: BM aspirates were collected from 817 patients at primary surgery. Tumor cells in BM were detected by immunocytochemistry using anticytokeratin antibodies (AE1/AE3). Analyses of the primary tumor included histologic grading, vascular invasion, and immunohistochemical detection of c-erbB-2, cathepsin D, p53, and estrogen receptor (ER)/progesterone receptor (PgR) expression. These analyses were compared with clinical outcome. The median follow-up was 49 months. Results: ITC were detected in 13.2% of the patients. The detection rate rose with increasing tumor size (P = .011) and lymph node involvement (P < .001). Systemic relapse and death from breast cancer occurred in 31.7% and 26.9% of the BM-positive patients versus 13.7% and 10.9% of BM-negative patients, respectively (P < .001). Analyzing node-positive and node-negative patients separately, ITC positivity was associated with poor prognosis in the node-positive group and in node-negative patients not receiving adjuvant therapy (T1N0). In multivariate analysis, ITC in BM was an independent prognostic factor together with node, tumor, and ER/PgR status, histologic grade, and vascular invasion. In separate analysis of the T1N0 patients, histologic grade was independently associated with both distant disease-free survival (DDFS) and breast cancer–specific survival (BCSS), ITC detection was associated with BCSS, and vascular invasion was associated with DDFS. Conclusion: ITC in BM is an independent predictor of DDFS and BCSS. An unfavorable prognosis was observed for node-positive patients and for node-negative patients not receiving systemic therapy. A combination of several independent prognostic factors can classify subgroups of patients into excellent and high-risk prognosis groups.

Download Full-text

Sarcopenia and osteopenia are negative predictors of postoperative survival in cholangiocellular carcinoma

10.1055/s-0041-1733736 ◽

2021 ◽

Author(s):

L Heinrichs ◽

S Loosen ◽

L Wittig ◽

V Keitel ◽

C Roderburg ◽

...

Keyword(s):

Cholangiocellular Carcinoma ◽

Postoperative Survival

Download Full-text

Circulating tumor cells: silent predictors of metastasis

F1000Research ◽

10.12688/f1000research.11313.1 ◽

2017 ◽

Vol 6 ◽

pp. 1445 ◽

Cited By ~ 23

Author(s):

LanLan Zhou ◽

David T. Dicker ◽

Elizabeth Matthew ◽

Wafik S. El-Deiry ◽

R. Katherine Alpaugh

Keyword(s):

Tumor Cells ◽

Circulating Tumor Cells ◽

Metastatic Disease ◽

Metastatic Breast ◽

Prognostic Indicator ◽

Disease Recurrence ◽

Curative Intent ◽

Early Detection Of Disease ◽

Mere Presence ◽

Intent To Treat

Circulating tumor cells (CTCs) were added to the arsenal of clinical testing in 2004 for three cancer types: metastatic breast, prostate, and colorectal cancer. CTCs were found to be an independent prognostic indicator of survival for these three diseases. Multiple enrichment/isolation strategies have been developed and numerous assay applications have been performed using both single and pooled captured/enriched CTCs. We have reviewed the isolation techniques and touched on many analyses. The true utility of a CTC is that it acts as a “silent” predictor of metastatic disease. The mere presence of a single CTC is an indication that disease has spread from the primary site. Comments and suggestions have been set forth for CTCs and cell-free DNA to be used as a screening panel for the early detection of disease recurrence and metastatic spread, providing the opportunity for early intervention with curative intent to treat metastatic disease.

Download Full-text